Group 1 - The company reported a revenue of 298 million yuan for the first three quarters of 2025, representing a year-on-year growth of 0.10% [1] - The net profit attributable to shareholders was 17.64 million yuan, showing a year-on-year decline of 32.22% [1] - The basic earnings per share were 0.24 yuan, which is a decrease of 35.14% compared to the previous year [1]

Group 1 - The company's Q3 revenue reached 117 million, representing a year-on-year increase of 14.76% [1] - The net profit for Q3 was 7.0493 million, showing a decline of 15.59% [1] - For the first three quarters, the total revenue was 298 million, with a slight increase of 0.10% [1] Group 2 - The net profit for the first three quarters was 17.6356 million, which is a decrease of 32.22% [1]

Core Viewpoint - Wanbang Pharmaceutical (301520) is actively monitoring opportunities in the upstream and downstream industrial layout of its main business, ensuring compliance with relevant laws and regulations, and confirming that there are no undisclosed significant matters [1] Summary by Categories - **Business Strategy** - The company is focused on the industrial layout opportunities related to its main business [1] - **Regulatory Compliance** - The company strictly adheres to relevant laws and regulations, indicating a commitment to transparency and governance [1] - **Disclosure Practices** - The company assures that it will fulfill its information disclosure obligations in a timely manner if any significant matters arise that require disclosure [1]

Core Viewpoint - Wanbang Medicine (301520.SZ) is identified as a CRO (Contract Research Organization) that specializes in providing professional pharmaceutical research outsourcing services to pharmaceutical companies and research institutions, specifically in clinical trial research services for cancer patients' medications [1] Company Overview - The company does not engage in the independent development of anti-cancer drugs, focusing solely on providing outsourced research services [1]

Core Viewpoint - The company, Wanbang Medical (301520.SZ), clarified that it is a CRO (Contract Research Organization) and does not engage in the independent research and development of anti-cancer drugs, although it provides clinical trial research services for cancer medications [1]. Group 1 - The company specializes in providing professional pharmaceutical research outsourcing services to pharmaceutical companies and research institutions [1]. - Wanbang Medical has undertaken projects that include providing clinical trial research technical services for medications used by cancer patients [1].

证券日报网讯万邦医药（301520）10月13日在互动平台回答投资者提问时表示，截至2025年9月30日， 公司的股东人数为8，086户。 ...

Core Viewpoint - Wanbang Medical (301520.SZ) currently has no innovative drug export business [1] Company Summary - The company has stated on its investor interaction platform that it does not engage in the export of innovative drugs at this time [1]

格隆汇10月13日丨万邦医药(301520.SZ)在投资者互动平台表示，公司目前暂无创新药出口业务。 ...

Group 1 - The company, Wanbang Medical (301520), reported that as of September 30, 2025, the number of its shareholders is 8,086 [1]

证券代码：301520 证券简称：万邦医药 公告编号：2025-053 安徽万邦医药科技股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日召开第二届董事会第十五次会议和第二届监事会第九次会议，审议通过了《关 于使用部分超募资金回购公司部分股份方案的议案》，同意公司使用超募资金以 集中竞价交易方式回购公司部分社会公众股股份并用于股权激励计划或员工持 股计划，用于回购股份的总金额为1,500万元-3,000万元，回购价格不超过60.62 元/股（含），具体回购股份的数量及金额以回购期满时实际回购的股份数量及金 额为准。本次回购的实施期限为董事会审议通过回购方案之日起 12 个月内。具 体内容详见公司于巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于使 用部分超募资金回购公司部分股份方案的公告》（公告编号：2024-040）和《回 购报告书》（公告编号：2024-042）。 鉴于公司已实施完成 2024 年前三季度权益分 ...